| SYNACT PHARMA AB |
| Schweden |
| Gesundheit |
| SE0008241491 / A2ALUN |
| 8F8 (Frankfurt) |
| FRA:8F8, ETR:8F8, 8F8:GR |
| - |
| https://synactpharma.com/ |
|
SynAct Pharma AB is a clinical-stage biotechnology company based in Lund, Sweden, specializing in the development of innovative medicines that induce resolution of inflammation rather than merely inhibiting it. Its lead candidate, resomelagon (AP1189..
>Volltext.. |
| 72.19 Mio. EUR |
| 72.47 Mio. EUR |
| - |
| - |
| -9.29 Mio. EUR |
| -0.17 EUR |
| 4.12 Mio. EUR |
| 3.83 Mio. EUR |
| -9.97 Mio. EUR |
| 3.29 |
| - |
| 3.43% |
| - |
| - |
| - |
| - |
| SYNACT |
| 18.11.26 |
|